C07K 14/161
Gag-pol
Official title: {gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40}
C07K14/161 (Gag-pol) appears on 46 US grants and 68 published applications in this corpus.
Search patents in C07K- Granted patents
- 46
- Published applications
- 68
- Assignees
- 49
- Inventors
- 101
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 1 | 2 |
| 2005 | 0 | 6 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 2 |
| 2009 | 6 | 2 |
| 2010 | 0 | 1 |
| 2011 | 2 | 2 |
| 2012 | 2 | 2 |
| 2013 | 0 | 5 |
| 2014 | 4 | 0 |
| 2015 | 2 | 2 |
| 2016 | 1 | 2 |
| 2017 | 1 | 0 |
| 2018 | 2 | 3 |
| 2019 | 2 | 8 |
| 2020 | 1 | 4 |
| 2021 | 3 | 7 |
| 2022 | 5 | 6 |
| 2023 | 3 | 4 |
| 2024 | 5 | 2 |
| 2025 | 2 | 2 |
| 2026 | 3 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Arc-based capsids and uses thereof5 May 2026US 12,617,822 B2Aera Therapeutics, Inc.
- Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes3 Mar 2026US 12,565,647 B2The Regents of the University of California
- Methods and constructs for production of lentiviral vector19 Aug 2025US 12,391,960 B2Lonza Walkersville, Inc.
- Methods and reagents for assessing the presence or absence of replication competent virus1 Apr 2025US 12,264,371 B2Juno Therapeutics, Inc.
- Engineered virus-like-particles for targeted capture of membrane proteins16 Jul 2026US 2026/0200991 A1
- Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides and Transgenes28 May 2026US 2026/0146247 A1The Regents of the University of California
- Stem cell based delivery of tumor-specific retroviral vectors21 May 2026US 2026/0139275 A1Abintus Bio, Inc.
- Delivery of heterologous proteins26 Feb 2026US 2026/0055146 A1Sana Biotechnology, Inc.
- Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same18 Dec 2025US 2025/0382334 A1President and Fellows of Harvard College
Most cited
By later US patents
- Monoclonal antibodies to human immunodeficiency virus and uses thereof24US 6,818,392 B2Abbott Laboratories · 2004
- Recombinant HCMV and RHCMV vectors and uses thereof20US 9,249,427 B2Oregon Health & Science University · 2016
- Recombinant HCMV and RHCMV vectors and uses thereof13US 9,982,241 B2Oregon Health & Science University · 2018
- Human cytomegalovirus comprising exogenous antigens4US 10,428,118 B2Oregon Health & Science University · 2019
- Multivalent HIV vaccine boost compositions and methods of use3US 11,098,086 B2GeoVax, Inc. · 2021